Real-time PCR Test Technology Assigned to Co-Diagnostics, Inc.

Co-Diagnostics, Inc. (“Company”) released today the transfer of certain real time PCR technology from DNA Logix, LLC to the Company pursuant to the execution of a purchase agreement.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Salt Lake City, UT (PRWEB) December 05, 2013

Co-Diagnostics, Inc. (“Company”) released today the transfer of certain real time PCR technology from DNA Logix, LLC to the Company pursuant to the execution of a purchase agreement. Under the terms of the agreement the Company exercised its option to purchase, and certain US Patents and Applications related to real time PCR diagnostics testing were transferred to the Company.

The four patents and applications transferred are titled “Methods of Preventing Non-Specific Reactions of Nucleotide Sequences”, “Rapid Oligo Probes”, “Detection Primers for Nucleic Acid Extensions or Amplification Reactions”, and “Primers for Nucleic Acid Extension or amplification Reactions”.

Company president Dwight Egan stated that “the patents transferred contain cutting edge technology in the molecular diagnostic testing industry and represent a breakthrough that will enable testing to be performed much less expensively than is standard in the industry at the present time”.

Real-time PCR testing detects the genetic signature of pathogens for rapid and accurate identification. However the high cost of test kits, machinery and training required to run the tests prevents its adoption in many countries around the world. The Company is devoted to improving access to diagnostics for infectious disease, such as real-time PCR test kits, and has dramatically lowered the price of testing. “

ENDS

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, is a Utah corporation based in Sandy, Utah that develops, manufactures and markets fully integrated DNA test systems. The Company’s intellectual property is based on mathematical principles that create algorithms in a unique DNA-based diagnostics system that is superior in cost and speed of development to all other such systems, both in the US and abroad.


Contact